

File No.- BMSIC/40030/839-2025/9690

दिनांक:- 10 / 12 / 2025

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, बिहार पटना  
BMSICL की निविदा संख्या- BMSIC/DRUGS/25-12 से संबंधित प्राप्त ई-निविदाओं के तकनीकी  
मूल्यांकन विवरणी पर साक्ष्य सहित दावा/आपत्ति की माँग संबंधी सूचना

बिहार चिकित्सा सेवाएं एवं आधारभूत संरचना निगम लि०, द्वारा औषधियों की अधिप्राप्ति हेतु ई-निविदा (निविदा संख्या- **BMSIC/DRUGS/25-12**) आमंत्रित की गई थी, जिसके आलोक में निर्धारित समय सीमा के अन्तर्गत कुल 13 (तेरह) ई-निविदा प्राप्त हुई। उक्त 13 (तेरह) ई-निविदा के दस्तावेजों के प्राथमिक तकनीकी मूल्यांकन के उपरान्त तैयार की गई तकनीकी मूल्यांकन विवरणी के दावा/आपत्ति के आमंत्रण हेतु BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** पर अपलोड की गई है।

निविदा में भाग लेने वाले निर्माता संस्थान अथवा अन्य आपूर्तिकर्ता अपलोड किये गए उपर्युक्त तकनीकी मूल्यांकन प्रपत्र में किसी प्रकार की विसंगति पाये जाने की स्थिति में, साक्ष्य सहित अपना दावा/आपत्ति दिनांक 17/12/2025 के अपराह्न 05:00 बजे तक केवल e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के माध्यम से कर सकते हैं।

e-proc 2.0 के **website (www.eproc2.bihar.gov.in)** के अलावा अन्य किसी माध्यम से प्राप्त किसी प्रकार के दावा/आपत्ति पर कोई विचार नहीं किया जायेगा।

अनुलग्नक- यथोक्त


  
महाप्रबंधक (अधिप्राप्ति)

ज्ञापांक:- BMSIC/40030/839-2025/9690

दिनांक:- 10 / 12 / 2025

प्रतिलिपि :- सहायक प्रबंधक (सिस्टम) एवं प्रबंधक (औषधि) को सूचनार्थ प्रेषित। निदेश है कि सूचना का अनुलग्नक सहित अविलंब BMSICL के **website (www.bmsicl.gov.in)** एवं e-proc2 (**www.eproc2.bihar.gov.in**) पर अपलोड करना सुनिश्चित करें।

  
महाप्रबंधक (अधिप्राप्ति)



## TENDER NO. BMSIC/DRUGS/25-12

## Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : -Unicare India Limited. Total Number of Pages Submitted in bid documents: - 1 to 243

| Sl. No | SBD clause serial No | Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Document/ fees submission status (Yes/ No) | Page number | Do the provided documents meet the eligibility criteria ? (Yes/ No) | Remarks                                                                                     |
|--------|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-------------|---------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| 1      | 3. (a)               | Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.                                                                                                                                                                                                                                                                                                                                                                                            | Yes                                        | 242         | Yes                                                                 |                                                                                             |
| 2      | 3.(b)                | EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount<br>1 Upto 5 drugs Rs1,00,000/- (One Lakh only)<br>2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only)<br>3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only)<br>4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only)<br>5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only) | Yes                                        | 131-135     | Yes                                                                 |                                                                                             |
| 3      | 3.(c)                | Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.                                                                                                                                                                                                                                                      | Yes                                        | 11-46       | Yes                                                                 |                                                                                             |
| 4      | 3.(l)                | Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than <b>25 Crores (Twenty-Five)</b> for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.<br>It's mandatory for the firm to provide a document for the Unique Document Identification Number (UDIN) to verify the documents.                                                                                                                               | Yes                                        | 216-224     | Yes                                                                 |                                                                                             |
| 5      | 3.(m)                | Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Yes                                        | 121-122     | No                                                                  | Copy of Income Tax Return Submitted for Only two Year i.e for F.Y-2023-2024 & F.Y-2024-2025 |
| 6      | 3.(p)                | Copy of PAN Card of the bidder company should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Yes                                        | 117         | Yes                                                                 |                                                                                             |
| 7      | 3.(q)                | Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Yes                                        | 123-128     | Yes                                                                 |                                                                                             |

Ankhan Singh

B. S. Singh




2/2

## TENDER NO. BMSIC/DRUGS/25-12

## Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 243

| Sl. No | SBD Clause serial No | Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Document/ fees submission status (Yes/ No) | Page Number as numbered by BMSICL | Do the provided documents meet the eligibility criteria ? (Yes/ No) | Remarks                                                                                                                                                                                                                                                                                                                                                    |
|--------|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|-----------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | 3.(d)                | The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Yes                                        | 48                                | Yes                                                                 |                                                                                                                                                                                                                                                                                                                                                            |
| 2      | 3.(e)                | Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Yes                                        | 1-2                               | Yes                                                                 |                                                                                                                                                                                                                                                                                                                                                            |
| 3      | 3.(f)                | Minimum three years old valid Manufacturing License of the quoted product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Yes                                        | 53-101                            | No                                                                  | (i) Pack size of NIT sr. no. 6 is not as per NIT.                                                                                                                                                                                                                                                                                                          |
| 4      |                      | Manufacturing License along with approved product list must be valid till the last date of the submission of tender.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Yes                                        | 53-101                            | No                                                                  | (ii) Product approval of NIT sl. No. 17 Less than three years.<br>(iii) Dosage form of NIT sr. no. 30, 32 & 58 is not as per NIT.                                                                                                                                                                                                                          |
| 5      |                      | Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender (Certificate should be enclosed with list of items) except for the drugs falling under the category of „New Drug“ as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.<br><b>Explanation-</b> In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945. For drugs with a patent that expired less than 2 years ago from the last date of bid submission: Non-patent holding bidders should submit a valid Market Standing Certificate and valid drug license, issued by the State Drug Licensing Authority in support of the claim. Bidders will be eligible only if one batch of new drug has been successfully manufactured/ imported for commercial use at the time of bidding. Bidders should submit document regarding patent expired less than 2 years ago from the last date of bid submission. | Yes                                        | 136-215                           | No                                                                  | (i) Not submitted for NIT sl. No. 17 & 40.<br>(ii) Submitted MSC of NIT sr. no. 6 specification & pack size is not as per NIT.<br>(iii) Submitted MSC of NIT sr. no. 30, 32 & 58 dosage form is not as per NIT.<br>(iv) Submitted MSC of quoted product NIT sr. no. 71 is not issued within preceding one year from the last date of submission of tender. |
| 6      |                      | For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NA                                         | NA                                | NA                                                                  |                                                                                                                                                                                                                                                                                                                                                            |

 17/11/25
  24/11/25
  27/11/25
  27/11/25


|    |       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |     |         |     |                                                                                                                                                                                                                                                                                                                                                           |
|----|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 7  |       | FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | NA  | NA      | NA  |                                                                                                                                                                                                                                                                                                                                                           |
| 8  |       | Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).                                                                                                                                                                                                                                                                                                                         | Yes | 102-110 | Yes |                                                                                                                                                                                                                                                                                                                                                           |
| 9  |       | Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.                                                                                                                                                                                                                                                                                                                                                                                                      | Yes | 53-101  | No  | (i) Pack size of NIT sr. no. 6 is not as per NIT.<br>(ii) Product approval of NIT sl. No. 17 Less than three years.<br>(iii) Dosage form of NIT sr. no. 30, 32 & 58 is not as per NIT.                                                                                                                                                                    |
| 10 | 3.(g) | In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.                                                                                                                                                                                                                             | NA  | NA      | NA  |                                                                                                                                                                                                                                                                                                                                                           |
| 11 | 3.(h) | Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. The Market Standing Certificate must have been issued within preceding one year from the last date of submission of tender. Self-attested copies are to be submitted.                                                                                                                                                                                                                                                                                                    | Yes | 136-215 | No  | (i) Not submitted for NIT sl. No. 17 & 40.<br>(ii) Submitted MSC of NIT sr. no. 6 specification & pack size is not as per NIT.<br>(iii) Submitted MSC of NIT sr. no. 30, 32 & 58 dosge form is not as per NIT.<br>(iv) Submitted MSC of quoted product NIT sr. no. 71 is not issued within preceding one year from the last date of submission of tender. |
| 12 | 3.(i) | Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.                                                                                                                                                                                                                                                                                                                                                                            | Yes | 111-113 | Yes |                                                                                                                                                                                                                                                                                                                                                           |
| 13 | 3.(j) | <b>WHO-GMP/GMP</b> (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted.<br><b>Explanation-</b> Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandis that the GMP certificate should remain valid till the date of submission of tender. | Yes | 51-52   | Yes |                                                                                                                                                                                                                                                                                                                                                           |
| 14 | 3.(k) | Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.                                                        | Yes | 114-116 | Yes |                                                                                                                                                                                                                                                                                                                                                           |

*[Signature]*  
17/11/25

*[Signature]*  
24/11/25

*[Signature]*  
27/11/25

|    |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |     |         |     |  |
|----|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|---------|-----|--|
| 15 | 3.(n)               | The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL asper <b>Annexure II.</b>                                                                                                        | Yes | 8-10    | Yes |  |
| 16 | 3. (o)              | List of items quoted in prescribed format as per <b>Annexure-III</b> duly signed.                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Yes | 3-5     | Yes |  |
| 17 | 5.(k)               | An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per <b>Annexure-IV.</b>                                                                                                                                                                                                                                                                                                                                                                                                | Yes | 129-130 | Yes |  |
| 18 | 5.(l)               | Filled check list as per given <b>Annexure-VI</b> to be submitted at the time of uploading the bid.                                                                                                                                                                                                                                                                                                                                                                                                                               | Yes | 225-226 | Yes |  |
| 19 | 7.(c)               | Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.                                                                                                                                                                                                                                                                    | Yes | 1-2     | Yes |  |
| 20 | 10.(c)              | If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.                                                                                                                                                                                                                                      | NA  | NA      | NA  |  |
| 21 | 2(d)<br>Explanation | <b>Explanation-</b> In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in <b>Annexure-VIII</b> | Yes | 239-240 | Yes |  |


15/11/25
24/11/25
27/11/25





## TENDER NO. BMSIC/DRUGS/25-12

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 243

Sheet to be used for verification of product approval and market standing

| Sl. No | NIT SL No | Name of the Quoted Drug                                 |                                                        | Pharmacopocial Specification/ Strength                                             |                                                                                                                                                                                                                                                                                                     | Dosage Form |                 | Pack Size                 |                                                                    | Approval Details           |               |                                 | Last 3yrs market standing certificate/<br>New Drug                                |
|--------|-----------|---------------------------------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------|---------------------------|--------------------------------------------------------------------|----------------------------|---------------|---------------------------------|-----------------------------------------------------------------------------------|
|        |           | As per NIT                                              | As per Approval                                        | As per NIT                                                                         | As per Approval                                                                                                                                                                                                                                                                                     | As per NIT  | As per Approval | As per NIT                | As per Approval                                                    | Approval From              | Approved Upto | Approved in Brand /Generic Name |                                                                                   |
| 1      | 3         | Amiodarone                                              | Amiodarone                                             | 200 mg                                                                             | 200 mg                                                                                                                                                                                                                                                                                              | Tablet      | Tablet          | 10 x 10                   | Not mentioned                                                      | 02.02.2017<br>(Page no.61) | 31.12.2026    | Generic                         | Submitted<br>(Page no.138)                                                        |
| 2      | 4         | Amisulpride                                             | Amisulpride                                            | 50 mg                                                                              | 50 mg                                                                                                                                                                                                                                                                                               | Tablet      | Tablet          | 10 x 10                   | Not mentioned                                                      | 12.01.2016<br>(Page no.62) | 19.11.2028    | Generic                         | Submitted<br>(Page no. 142)                                                       |
| 3      | 6         | Artesunate (A) +<br>Sulphadoxine -<br>Pyrimethamine (B) | Antimalarial Combi Blister Pack<br>(15 year and above) | Combi pack (A+B)<br>1 Tablet 200 mg (A) +<br>2 Tablet<br>(750 mg + 37.5 mg)<br>(B) | Each combi blister pack contain:-<br>Artesunate Tablets 200 mg (AS) (3<br>Tablets) -<br>Each Tablet contains:<br>Artesunate IP 200 mg &<br>Primethamine and Sulphadoxine Tablets<br>IP (SP) (2 Tablets)<br>Each uncoated Tablets contains:-<br>Pyrimethamine IP 37.5 mg &<br>Sulphadoxine IP 750 mg | Tablet      | Tablet          | One Combi<br>Blister Pack | One Combi<br>Blister Pack<br>Contain 5 Tablets<br>(Not as per NIT) | 28.11.2019<br>(Page no.63) | 31.12.2026    | Generic                         | Submitted MSC<br>specification & pack<br>size is not as per NIT<br>(Page no. 148) |
| 4      | 10        | Chlordiazepoxide                                        | Chlordiazepoxide                                       | 10 mg                                                                              | 10 mg                                                                                                                                                                                                                                                                                               | Tablet      | Tablet          | 10 x 10                   | Not mentioned                                                      | 02.02.2017<br>(Page no.67) | 31.12.2026    | Generic                         | Submitted<br>(Page no. 149)                                                       |

 17/11/25  
 24/11/25  
 27/11/25  


|    |    |                |                |       |       |           |           |         |               |                                                          |            |         |                             |
|----|----|----------------|----------------|-------|-------|-----------|-----------|---------|---------------|----------------------------------------------------------|------------|---------|-----------------------------|
| 5  | 11 | Clobazam       | Clobazam       | 5 mg  | 5 mg  | Tablet    | Tablet    | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.68)                               | 31.12.2026 | Generic | Submitted<br>(Page no. 150) |
| 6  | 12 | Clobazam       | Clobazam       | 10 mg | 10 mg | Tablet    | Tablet    | 10 x 10 | Not mentioned | 21.01.2016<br>(Page no.69)                               | 19.11.2028 | Generic | Submitted<br>(Page no.159)  |
| 7  | 13 | Clozapine      | Clozapine      | 50 mg | 50 mg | Tablet    | Tablet    | 10 x 10 | Not mentioned | 21.01.2016<br>(Page no. 70)                              | 19.11.2028 | Generic | Submitted<br>(Page no.165)  |
| 8  | 17 | Dapagliflozine | Dapagliflozine | 10 mg | 10 mg | Tablet    | Tablet    | 10 x 10 | Not mentioned | 23.07.2024<br>(Page no.72)<br>(Less than<br>three years) | 19.11.2028 | Generic | Not submitted               |
| 9  | 20 | Desvenlafaxine | Desvenlafaxine | 50 mg | 50 mg | ER Tablet | ER Tablet | 10 x 10 | Not mentioned | 21.01.2016<br>(Page no.73)                               | 19.11.2028 | Generic | Submitted<br>(Page no.161)  |
| 10 | 21 | Diazepam       | Diazepam       | 5 mg  | 5 mg  | Tablet    | Tablet    | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.74)                               | 31.12.2026 | Generic | Submitted<br>(Page no.168)  |
| 11 | 22 | Diltiazem      | Diltiazem      | 30 mg | 30 mg | Tablet    | Tablet    | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.74)                               | 31.12.2026 | Generic | Submitted<br>(Page no.168)  |




*Dr. Hashim*  
17/11/25

*Alch*  
24/11/25

*SKR*  
27/11/25

207

|    |    |                                    |                                    |                          |                       |                      |                                                         |             |               |                            |            |         |                                                                 |
|----|----|------------------------------------|------------------------------------|--------------------------|-----------------------|----------------------|---------------------------------------------------------|-------------|---------------|----------------------------|------------|---------|-----------------------------------------------------------------|
| 12 | 24 | Donepezil                          | Donepezil                          | 5 mg                     | 5 mg                  | Tablet               | Tablet                                                  | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.75) | 31.12.2026 | Generic | Submitted<br>(Page no.169)                                      |
| 13 | 25 | Efavirenz                          | Efavirenz                          | 200 mg                   | 200 mg                | Tablet               | Tablet                                                  | 30's Bottle | Not mentioned | 21.01.2016<br>(Page no.76) | 19.11.2028 | Generic | Submitted<br>(Page no.171)                                      |
| 14 | 27 | Flunarizine                        | Flunarizine                        | 5 mg                     | 5 mg                  | Tablet               | Tablet                                                  | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.77) | 31.12.2026 | Generic | Submitted<br>(Page no.174)                                      |
| 15 | 28 | Flunarizine                        | Flunarizine                        | 10 mg                    | 10 mg                 | Tablet               | Tablet                                                  | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.77) | 31.12.2026 | Generic | Submitted<br>(Page no.174)                                      |
| 16 | 30 | Glyceryl trinitrate                | Nitroglycerin                      | 2.6 mg                   | 2.6 mg                | Tablet               | Controlled<br>Release<br>Tablets<br>(Not as per<br>NIT) | 10 x 10's   | Not mentioned | 21.01.2016<br>(Page no.78) | 19.11.2028 | Generic | Submitted MSC dosage<br>form is not as per NIT<br>(Page no.179) |
| 17 | 32 | Isosorbide dinitrate               | Isosorbide dinitrate               | 5 mg                     | 5 mg                  | Sublingual<br>Tablet | Tablet<br>(Not as per<br>NIT)                           | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.80) | 31.12.2026 | Generic | Submitted MSC dosage<br>form is not as per NIT<br>(Page no.163) |
| 18 | 33 | Lamivudine (A) +<br>Zidovudine (B) | Lamivudine (A) +<br>Zidovudine (B) | 30 mg (A) + 60 mg<br>(B) | 30 mg (A) + 60 mg (B) | Tablet               | Tablet                                                  | 30's Bottle | Not mentioned | 03.09.2021<br>(Page no.81) | 19.11.2028 | Generic | Submitted<br>(Page no.163)                                      |

 17/11/25
 24/11/25
 27/11/25

|    |    |                                  |                                  |                           |                           |        |        |             |               |                            |            |         |                            |
|----|----|----------------------------------|----------------------------------|---------------------------|---------------------------|--------|--------|-------------|---------------|----------------------------|------------|---------|----------------------------|
| 19 | 34 | Levodopa (A) +<br>Carbidopa (B)  | Levodopa (A) +<br>Carbidopa (B)  | 100 mg (A) + 10 mg<br>(B) | 100 mg (A) + 10 mg<br>(B) | Tablet | Tablet | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.82) | 31.12.2026 | Generic | Submitted<br>(Page no.180) |
| 20 | 35 | Lithium                          | Lithium                          | 300 mg                    | 300 mg                    | Tablet | Tablet | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.83) | 31.12.2026 | Generic | Submitted<br>(Page no.180) |
| 21 | 36 | Lopinavir (A) +<br>Ritonavir (B) | Lopinavir (A) +<br>Ritonavir (B) | 100 mg (A) + 25 mg<br>(B) | 100 mg (A) + 25 mg<br>(B) | Tablet | Tablet | 30's Bottle | Not mentioned | 21.01.2026<br>(Page no.84) | 19.11.2028 | Generic | Submitted<br>(Page no.171) |
| 22 | 38 | Methyldopa                       | Methyldopa                       | 250 mg                    | 250 mg                    | Tablet | Tablet | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.85) | 31.12.2026 | Generic | Submitted<br>(Page no.181) |
| 23 | 39 | Mitrazapine                      | Mitrazapine                      | 15 mg                     | 15 mg                     | Tablet | Tablet | 10 x 10     | Not mentioned | 09.02.2018<br>(Page no.86) | 31.12.2026 | Generic | Submitted<br>(Page no.187) |
| 24 | 40 | Mycophenolate mofetil            | Mycophenolate mofetil            | 250 mg                    | 250 mg                    | Tablet | Tablet | 10 x 10     | Not mentioned | 21.01.2016<br>(Page no.87) | 19.11.2028 | Generic | Not submitted              |
| 25 | 45 | Olanzapine                       | Olanzapine                       | 2.5 mg                    | 2.5 mg                    | Tablet | Tablet | 10 x 10     | Not mentioned | 02.02.2017<br>(Page no.88) | 31.12.2026 | Generic | Submitted<br>(Page no.190) |

*Shah*  
17/11/25 *AKHP* 24/11/25 *S/K* 27/11/25

|    |    |                  |                                                        |        |        |        |                                                      |         |               |                            |            |         |                                                                  |
|----|----|------------------|--------------------------------------------------------|--------|--------|--------|------------------------------------------------------|---------|---------------|----------------------------|------------|---------|------------------------------------------------------------------|
| 26 | 47 | Pioglitazone     | Pioglitazone                                           | 30 mg  | 30 mg  | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.89) | 31.12.2026 | Generic | Submitted<br>(Page no.191)                                       |
| 27 | 51 | Propranolol      | Propranolol                                            | 10 mg  | 10 mg  | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.90) | 31.12.2026 | Generic | Submitted<br>(Page no.191)                                       |
| 28 | 52 | Pyrazinamide     | Pyrazinamide                                           | 500 mg | 500 mg | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.93) | 31.12.2026 | Generic | Submitted<br>(Page no.192)                                       |
| 29 | 53 | Pyrazinamide     | Pyrazinamide                                           | 750 mg | 750 mg | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.93) | 31.12.2026 | Generic | Submitted<br>(Page no.192)                                       |
| 30 | 56 | Risperidone      | Risperidone                                            | 2 mg   | 2 mg   | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 21.01.2016<br>(Page no.94) | 19.11.2028 | Generic | Submitted<br>(Page no.196)                                       |
| 31 | 58 | Sodium valproate | Sodium valproate Gastro Resistant<br>Tablets IP 500 mg | 500 mg | 500 mg | Tablet | Gastro<br>Resistant<br>Tablet<br>(Not as per<br>NIT) | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.96) | 31.12.2026 | Generic | Submitted MSC dosage<br>form is not as per NIT<br>(Page no. 201) |
| 32 | 59 | Spironolactone   | Spironolactone                                         | 25 mg  | 25 mg  | Tablet | Tablet                                               | 10 x 10 | Not mentioned | 02.02.2017<br>(Page no.96) | 31.12.2026 | Generic | Submitted<br>(Page no.202)                                       |

*Shahin*  
19/11/25

*MHP*  
24/11/25

*SK*  
27/11/25

*202*

|    |    |                                                      |                                                      |                                         |                                      |         |         |             |               |                             |            |         |                                                                                                                                |
|----|----|------------------------------------------------------|------------------------------------------------------|-----------------------------------------|--------------------------------------|---------|---------|-------------|---------------|-----------------------------|------------|---------|--------------------------------------------------------------------------------------------------------------------------------|
| 33 | 62 | Tacrolimus                                           | Tacrolimus                                           | 2 mg                                    | 2 mg                                 | Capsule | Capsule | 10 x 10     | Not mentioned | 11.01.2018<br>(Page no.97)  | 31.12.2026 | Generic | Submitted<br>(Page no.205)                                                                                                     |
| 34 | 66 | Trifluoperazin                                       | Trifluoperazin                                       | 5 mg                                    | 5 mg                                 | Tablet  | Tablet  | 10 x 10     | Not mentioned | 11.01.2018<br>(Page no.99)  | 31.12.2026 | Generic | Submitted<br>(Page no.207)                                                                                                     |
| 35 | 69 | Verapamil                                            | Verapamil                                            | 40 mg                                   | 40 mg                                | Tablet  | Tablet  | 10 x 10's   | Not mentioned | 02.02.2017<br>(Page no.100) | 31.12.2026 | Generic | Submitted<br>(Page no.208)                                                                                                     |
| 36 | 71 | Zidovudine (A) +<br>Lamivudine (B) +<br>Nevirapine © | Zidovudine (A) +<br>Lamivudine (B) +<br>Nevirapine © | 60 mg (A) + 30 mg<br>(B)<br>+ 50 mg (C) | 60 mg (A) + 30 mg (B)<br>+ 50 mg (C) | Tablet  | Tablet  | 60's Bottle | Not mentioned | 10.08.2013<br>(Page no.101) | 19.11.2028 | Generic | Submitted MSC is not<br>issued within preceding<br>one year from the last<br>date of submission of<br>tender.<br>(Page no.210) |

*[Handwritten signatures and dates]*  
17/11/25      24/11/25      27/11/25



## TENDER NO. BMSIC/DRUGS/25-12

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Unicare India Ltd. Total Number of Pages Submitted in bid documents:- 243

## Sheet for verification of licence details

| Sl. No. | NIT Sl. No | Name of the Drug as per NIT                             | Manufacturer |                              | Importer     |                       | Validity                    |                            | GMP/ WHO GMP/ COPP (Import) |                            |
|---------|------------|---------------------------------------------------------|--------------|------------------------------|--------------|-----------------------|-----------------------------|----------------------------|-----------------------------|----------------------------|
|         |            |                                                         | Forms Number | Manufacturing license Number | Forms Number | Import license Number | From                        | To                         | From                        | To                         |
| 1       | 3          | Amiodarone                                              | 25           | 3 of 1984                    | NA           | NA                    | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024                  | 21.11.2025<br>(Page no.51) |
| 2       | 4          | Amisulpride                                             | 25           | 30/UA/2006                   | NA           | NA                    | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024                  | 19.09.2027<br>(Page no.52) |
| 3       | 6          | Artesunate (A) +<br>Sulphadoxine -<br>Pyrimethamine (B) | 25           | 3 of 1984                    | NA           | NA                    | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024                  | 21.11.2025<br>(Page no.51) |
| 4       | 10         | Chlordiazepoxide                                        | 25           | 3 of 1984                    | NA           | NA                    | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024                  | 21.11.2025<br>(Page no.51) |
| 5       | 11         | Clobazam                                                | 25           | 3 of 1984                    | NA           | NA                    | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024                  | 21.11.2025<br>(Page no.51) |
| 6       | 12         | Clobazam                                                | 25           | 30/UA/2006                   | NA           | NA                    | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024                  | 19.09.2027<br>(Page no.52) |

 17/11/24
  24/11/24
  27/11/25

|    |    |                |    |            |    |    |                             |                            |            |                            |
|----|----|----------------|----|------------|----|----|-----------------------------|----------------------------|------------|----------------------------|
| 7  | 13 | Clozapine      | 25 | 30/UA/2006 | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 8  | 17 | Dapagliflozine | 25 | 30/UA/2006 | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 9  | 20 | Desvenlafaxine | 25 | 30/UA/2006 | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 10 | 21 | Diazepam       | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 11 | 22 | Diltiazem      | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 12 | 24 | Donepezil      | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 13 | 25 | Efavirenz      | 25 | 30/UA/2006 | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 14 | 27 | Flunarizine    | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 15 | 28 | Flunarizine    | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |

17/11/25 24/11/25 27/11/25

|    |    |                                    |               |                                    |    |    |                               |                            |            |                            |
|----|----|------------------------------------|---------------|------------------------------------|----|----|-------------------------------|----------------------------|------------|----------------------------|
| 16 | 30 | Glyceryl trinitrate                | 25            | 30/UA/2006                         | NA | NA | 21.11.2013<br>(Page no.57)    | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 17 | 32 | Isosorbide dinitrate               | 25            | 3 of 1984                          | NA | NA | 03.01.1984<br>(page no. 53)   | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 18 | 33 | Lamivudine (A) +<br>Zidovudine (B) | 25<br>&<br>28 | 30/UA/2006<br>&<br>30/UA/SC/P-2006 | NA | NA | 21.11.2013<br>(Page no.57-58) | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 19 | 34 | Levodopa (A) +<br>Carbidopa (B)    | 25            | 3 of 1984                          | NA | NA | 03.01.1984<br>(page no. 53)   | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 20 | 35 | Lithium                            | 25            | 3 of 1984                          | NA | NA | 03.01.1984<br>(page no. 53)   | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 21 | 36 | Lopinavir (A) +<br>Ritonavir (B)   | 25            | 30/UA/2006                         | NA | NA | 21.11.2013<br>(Page no.57)    | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 22 | 38 | Methyldopa                         | 25            | 3 of 1984                          | NA | NA | 03.01.1984<br>(page no. 53)   | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 23 | 39 | Mitrazapine                        | 25<br>&<br>28 | 30/UA/2006<br>&<br>30/UA/SC/P-2006 | NA | NA | 21.11.2013<br>(Page no.57-58) | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 24 | 40 | Mycophenolate mofetil              | 25            | 30/UA/2006                         | NA | NA | 21.11.2013<br>(Page no.57)    | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |

*[Signature]*  
17/11/25

*[Signature]*  
24/11/25  
27/11/25

|    |    |                  |    |                |    |    |                             |                            |            |                            |
|----|----|------------------|----|----------------|----|----|-----------------------------|----------------------------|------------|----------------------------|
| 25 | 45 | Olanzapine       | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 26 | 47 | Pioglitazone     | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 27 | 51 | Propranolol      | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 28 | 52 | Pyrazinamide     | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 29 | 53 | Pyrazinamide     | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 30 | 56 | Risperidone      | 25 | 30/UA/2006     | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |
| 31 | 58 | Sodium valproate | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 32 | 59 | Spironolactone   | 25 | 3 of 1984      | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 33 | 62 | Tacrolimus       | 28 | 3/SC/P of 1984 | NA | NA | 03.01.1984<br>(page no. 54) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |

*[Handwritten signatures and dates]*  
17/11/24  
24/11/24  
27/11/25

|    |    |                                                      |    |            |    |    |                             |                            |            |                            |
|----|----|------------------------------------------------------|----|------------|----|----|-----------------------------|----------------------------|------------|----------------------------|
| 34 | 66 | Trifluoperazin                                       | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 35 | 69 | Verapamil                                            | 25 | 3 of 1984  | NA | NA | 03.01.1984<br>(page no. 53) | 31.12.2026<br>(Page no.56) | 22.11.2024 | 21.11.2025<br>(Page no.51) |
| 36 | 71 | Zidovudine (A) +<br>Lamivudine (B) +<br>Nevirapine © | 25 | 30/UA/2006 | NA | NA | 21.11.2013<br>(Page no.57)  | 19.11.2028<br>(Page no.60) | 20.09.2024 | 19.09.2027<br>(Page no.52) |

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/839-2025/8593 dt 07.11.2025 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due deligence and care.Inspite, some inadvertent discreprencies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discreprencies are observed for rectification.

*[Signature]*  
17/11/25

*[Signature]*  
24/11/25

*[Signature]*  
27/11/25